Samik Basu
Chief Scientific Officer Cabaletta Bio
Samik Basu, M.D., is Chief Scientific Officer at Cabaletta, where he oversees all discovery, preclinical, computational biology, and translational medicine research. He joined Cabaletta in December 2019 and previously served as Vice President of Preclinical Research and Translational Medicine. Prior to Cabaletta, he was Head of Translational Sciences at Adaptimmune Therapeutics and earlier co-led preclinical development efforts for Keytruda (pembrolizumab) at Merck Research Laboratories. He is a physician-scientist with 20+ years of industry and academic experience and received his M.D. from Temple University.
Seminars
Wednesday 16th September 2026
Proving Durable Autoimmune Responses Without Lymphodepletion to Expand Safety, Access & Clinical Impact
11:15 am
- Showcasing autoimmune clinical data achieved without lymphodepletion to demonstrate durable responses while improving patient safety and tolerability
- Sharing evolving PK profiles to illustrate sustained persistence and strengthen confidence in non-conditioning approaches
- Evaluating safety outcomes and patient engagement benefits to positioning nonconditioning approaches as an accessible and scalable therapeutic strategy
